# A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

> **NCT00067951** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 190 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** rosiglitazone/metformin

## Key facts

- **NCT ID:** NCT00067951
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10-17
- **Primary completion:** 2004-11-01
- **Final completion:** 2004-11-30
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00067951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00067951, "A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00067951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*